Overview
Description
CSL Limited is a leading biotechnology company specializing in the research, development, manufacturing, and marketing of innovative biopharmaceutical products. The company's core activities focus on producing therapies for serious human medical conditions, particularly in the areas of immunology, hematology, and rare diseases. A key business segment, CSL Seqirus, is one of the world's largest influenza vaccine providers, supplying governments and healthcare systems with seasonal and pandemic influenza solutions. CSL Limited also operates in related fields such as plasma-derived therapies, recombinant proteins, and specialty pharmaceuticals, serving patients in global healthcare markets. Its operations significantly impact the pharmaceutical and healthcare sectors, often advancing treatments in emerging and critical areas of medicine. With a diverse product portfolio and a commitment to R&D, CSL Limited plays a vital role in driving forward innovations in disease prevention and treatment.
About
CEO
Dr. Paul F. McKenzie Ph.D.
Employees
32698
Address
655 Elizabeth Street
Melbourne, 3000, VIC
Australia
Melbourne, 3000, VIC
Australia
Phone
61 3 9389 1911
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Australia
MIC code
XASX